| A comparison of the cost effectiveness of alternative prophylactic therapies in childhood asthma. | |
| | |
MedLine Citation:
|
PMID: 10163573 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
An economic analysis was conducted comparing the cost effectiveness of fluticasone propionate with that of sodium cromoglycate (cromolyn sodium) in a group of children aged 4 to 12 years old with asthma, who required inhaled prophylactic therapy. Over an 8-week study period, 115 patients received sodium cromoglycate 20mg 4 times daily, via the spin operated dry powder inhaler, and 110 patients received fluticasone propionate 50 micrograms twice daily, via the Diskhaler (trademark held by the Glaxo Wellcome Group of Companies). Patient healthcare resource use was examined in terms of study medication, the use of rescue medication [salbutamol (albuterol) 200 micrograms] and the number of hospitalisations. The effectiveness of both treatments was examined over a range of success and failure criteria embracing peak expiratory flow rate (PEFR) improvement, symptom control and the level of adverse events related to the study medication. Results indicate that, for each UK pound spent, fluticasone propionate was associated with twice as many successfully treated patients as sodium cromoglycate, using a range of outcomes based on the goals of treatment defined in the British Thoracic Society's asthma guidelines. It is concluded that fluticasone propionate was more cost effective than sodium cromoglycate in improving PEFR and symptom control in this group of children with asthma who had a clinical requirement for prophylactic therapy. |
| | |
Authors:
|
P C Booth; N E Wells; A K Morrison |
Related Documents
:
|
10931123 - Effect of a 4-week treatment with theophylline on sputum eosinophilia and sputum eosino... 12929143 - Adverse work outcomes and events attributed to asthma. 9347533 - Assessment of hearing-impaired athletes' anxiety and self-perceptions. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: PharmacoEconomics Volume: 10 ISSN: 1170-7690 ISO Abbreviation: Pharmacoeconomics Publication Date: 1996 Sep |
Date Detail:
|
Created Date: 1996-12-05 Completed Date: 1996-12-05 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9212404 Medline TA: Pharmacoeconomics Country: NEW ZEALAND |
Other Details:
|
Languages: eng Pagination: 262-8 Citation Subset: T |
Affiliation:
|
Health Economics Group, Glaxo Wellcome UK Ltd, Uxbridge, Middlesex, England. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Androstadienes / administration & dosage, economics*, therapeutic use Anti-Asthmatic Agents / administration & dosage, economics*, therapeutic use Asthma / economics*, physiopathology, prevention & control* Child Cost-Benefit Analysis Cromolyn Sodium / administration & dosage, economics*, therapeutic use Great Britain Humans Peak Expiratory Flow Rate |
| Chemical | |
Reg. No./Substance:
|
0/Androstadienes; 0/Anti-Asthmatic Agents; 15826-37-6/Cromolyn Sodium; 90566-53-3/fluticasone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dynamic competition as an exploratory model of healthcare policy for the antihypertensive market.
Next Document: Impact of selective financing of drugs on pharmaceutical expenditure control in the province of Vall...